Economy

2024-01-08 15:02:39

Staying safe on the highway involves more than just obeying speed limits; it requires a proactive approach to driving. Oleg Shatov, head of the Kazan Higher School of Driving, provides valuable information on how to avoid mass traffic accidents, emphasizing the importance of observation and timely response.

Driving at an optimal speed is critical to recognizing and responding to potential highway hazards. Maintaining optimal speed allows the driver to improve visibility and reaction time. In adverse weather conditions or when visibility is limited, you should reduce your speed in advance.

One of the key aspects of safe driving is the ability to anticipate and quickly respond to unfolding situations. Shatov notes that even when drivers notice that brake lights and hazard warning lights are going off in front of their car, they react with a worrying delay, sometimes as much as six seconds, which can be critical in situations such as an approaching traffic jam or major accident. Predictive braking, initiated at the first sign of potential danger, can help prevent collisions (photo: ru.freepik.com).

While navigation systems are valuable tools for drivers, Shatov highlights a significant drawback. The information provided by navigators may not always be timely or accurate when it comes to predicting upcoming major accidents. Updates often occur with a delay of several minutes, which can be a significant gap in the dynamic driving experience. Relying solely on navigation information may not be sufficient to ensure timely response to rapidly changing road conditions.

1704729593
#Russians #revealed #secret #avoid #mass #accidents #highway

2024-01-08 13:56:14

By Le Figaro with AFP

Published 1 hour ago, Updated 1 hour ago

Johnson & Johnson will pay $2 billion to buy Ambrx JHVEPhoto – stock.adobe.com

The American laboratory has announced its intention to acquire the start-up specializing in treatment research once morest several types of cancer.

To acquire a new portfolio of molecules, the American laboratory Johnson & Johnson had to release its own. In a press release published this Monday, January 8, the company announced the acquisition of the Californian biotech Ambrx for around $2 billion in order to strengthen its position in the treatment of cancer.

With this operation, Johnson & Johnson will get its hands on several molecules in development for several types of cancers. They use specific antibodies called “armed” (ADCs or «Antibody Drug Conjugates»), considered particularly promising.

Promising treatments once morest breast and prostate cancers

The ADCs, manufactured in the laboratory, are coupled to an anti-cancer molecule which they will bring precisely to where the tumor is located. Ambrx’s lead product in development, ARX517, is in clinical development for metastatic prostate cancer. The biotech is also developing other molecules, including one for breast cancer. The acquisition should be finalized during the first half of 2024, specifies J&J, which will pay $28 for each Ambrx share. The latter’s stock ended Friday at $13.63.

The major global laboratories, which have garnered strong revenues during the Covid-19 pandemic, are competing in oncology, which has become one of the most buoyant and lucrative sectors of the pharmaceutical industry in recent years. Johnson & Johnson, which reported nearly $95 billion in annual sales in 2022, will report its 2023 annual results on January 23. In electronic trading before the opening of the New York Stock Exchange, its title fell very slightly by 0.2% to 160.74 dollars.

”
data-script=”
>

1704727800
#Johnson #Johnson #buys #biotech #Ambrx #billion

2024-01-08 13:17:11

Jan. 8 – ** Shares of Crocs CROX.O rose more than 8% to $93.50 premarket following the rubber clog maker raised its fourth-quarter sales forecast

**The company now expects fourth-quarter revenue to increase more than 1%, compared to previously forecasting a decline of 1% to 4%, due to a successful holiday season

**The company adds that it saw market share gains for the Crocs and Heydude brands during the holiday season

**CROX also provides preliminary forecasts for 2024, projecting revenue growth of 3% to 5%; analysts expect 4.4% increase, LSEG data shows

**The company expects adjusted operating margins of approximately 25% for 2024

**Yoga clothing maker Lululemon Athletica

LULU.O and clothing chains Abercrombie & Fitch ANF.N and American Eagle Outfitters AEO.N also raised their guidance for the holiday quarter due to strong demand

**CROX shares have fallen ~14% over the past 12 months

1704726108
#Crocs #raises #sales #forecast #fourth #quarter #p.m